Study of he Biophysical Mechanisms Regulating the Efficacy of Orally Administered

项目4正在处理口服化疗药物在被系统吸收并到达靶肿瘤组织的过程中遇到的各种物理障碍。例如，这些障碍包括：胃肠道(Gl)的pH值变化，酶降解，通过不同机制进行的上皮运输。为了研究和解决这些障碍，我们将使用我们的工程聚合物载体。该项目由Nicholas Peppas博士领导，使用项目1中描述的Fidler博士的动物模型。Nicholas Peppas博士是UTA化学系、生物医学工程系和制药学系的教授，Fletcher S.Pratt工程系主任。佩帕斯博士是生物纳米技术和分子识别过程、受控药物输送纳米设备和智能生物材料领域的世界领先者。在其他医疗设备中，他开发了人工晶状体、声带修复材料、用于I型糖尿病患者口服胰岛素的纳米给药系统，以及用于治疗患有骨质疏松症的绝经后妇女的降钙素口服给药系统，并已获得专利和/或商业化。佩帕斯博士是美国国家工程院院士、国家科学院医学研究所院士和法国药学院院士。

Project 4 is dealing with various physical barriers that chemotherapeutical agent administered orally meets on its way to be systemically absorbed and to reach the target tumor tissue. These barriers include for example: changes in pH across the gastrointestinal (Gl) tract, enzymatic degradation, epithelial transport through different mechanisms. To study and tackle these barriers we will use our engineered polymeric carriers. This project is led by Dr. Nicholas Peppas using animal models of Dr. Fidler as described in Project 1. Dr. Nicholas Peppas is a Professor in the Departments of Chemical, Biomedical Engineering and Pharmaceutics and Fletcher S. Pratt Chair of Engineering at UTA. Dr. Peppas is a world leader in the fields of bionanotechnology and molecular recognition processes, nanodevices for controlled drug delivery, and intelligent biomaterials. Among other medical devices, he has developed, patented and/or commercialized intraocular lenses, materials for vocal cord restoration, nanodelivery systems for oral administration of insulin to type I diabetic patients, and systems for oral delivery of calcitonin for treatment of postmenopausal women suffering from osteoporosis. Dr. Peppas is a member of the National Academy of Engineering, a member of the Institute of Medicine of the National Academy of Sciences and the French Academy of Pharmacy.